These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33534211)

  • 1. Immunophenotypic Differences in Tumor-Infiltrating Lymphocytes and Neovascularization Between Primary Cutaneous Melanoma With and Without Metastasis: An Immunohistochemical Study of 80 Cases.
    Salgüero I; Roustán G; Requena L; Suárez D; García-Fresnadillo D; Redondo JI; Nájera L
    Am J Dermatopathol; 2021 Nov; 43(11):811-818. PubMed ID: 33534211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma.
    Fujii H; Arakawa A; Utsumi D; Sumiyoshi S; Yamamoto Y; Kitoh A; Ono M; Matsumura Y; Kato M; Konishi K; Shiga T; Sano S; Sakaguchi S; Miyagawa-Hayashino A; Takahashi K; Uezato H; Miyachi Y; Tanioka M
    Int J Cancer; 2014 May; 134(10):2393-402. PubMed ID: 24243586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
    Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
    Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes.
    Googe PB; Flores K; Jenkins F; Merritt B; Moschos SJ; Grilley-Olson JE
    Am J Dermatopathol; 2021 Aug; 43(8):556-559. PubMed ID: 33156018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
    Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
    Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
    Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma.
    Walsh NM; Fleming KE; Hanly JG; Dakin Hache K; Doucette S; Ferrara G; Cerroni L
    Hum Pathol; 2016 Jun; 52():190-6. PubMed ID: 26980039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
    Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
    Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vast majority of lymphocytes infiltrating primary cutaneous melanoma express the CD27 costimulatory receptor: implications for melanoma progression.
    Pepe CA; Ricci R; Cortelazzi C; Mori G; Zambito F; Campanini N; Aimi F; Santoro S; Lombardi M; Santini M; de Panfilis G
    Eur J Dermatol; 2011; 21(2):178-83. PubMed ID: 21382782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
    Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
    PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes.
    Lee WJ; Lee YJ; Shin HJ; Won CH; Chang SE; Choi JH; Lee MW
    Melanoma Res; 2018 Oct; 28(5):423-434. PubMed ID: 29634635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
    Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
    Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory cell infiltrates in advanced metastatic uveal melanoma.
    Krishna Y; McCarthy C; Kalirai H; Coupland SE
    Hum Pathol; 2017 Aug; 66():159-166. PubMed ID: 28655639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma.
    De Panfilis G; Campanini N; Santini M; Mori G; Tognetti E; Maestri R; Lombardi M; Froio E; Ferrari D; Ricci R
    J Invest Dermatol; 2008 Mar; 128(3):676-84. PubMed ID: 17851585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of FOXP3 in Canine Gliomas: Immunohistochemical Study of Tumor-Infiltrating Regulatory Lymphocytes.
    Pi Castro D; José-López R; Fernández Flores F; Rabanal Prados RM; Mandara MT; Arús C; Pumarola Batlle M
    J Neuropathol Exp Neurol; 2020 Feb; 79(2):184-193. PubMed ID: 31846038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference in immunohistochemical findings among anti-PD-L1 antibodies and their relationships with CD4+ and CD8+ T cells in Japanese melanoma patients.
    Yoneta D; Kato J; Kamiya T; Horimoto K; Sato S; Sawada M; Minowa T; Hida T; Sugita S; Uhara H
    Int J Clin Oncol; 2022 Aug; 27(8):1364-1371. PubMed ID: 35650364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
    Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
    Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma.
    Bi Y; Ge L; Ren X; Pang J; Zhao Y; Liang Z
    Clin Transl Oncol; 2022 May; 24(5):941-949. PubMed ID: 35064455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.